# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cowen & Co. analyst Joshua Jennings downgrades Apollo Endosurgery (NASDAQ:APEN) from Outperform to Market Perform and lo...
Apollo Endosurgery's (NASDAQ:APEN) short percent of float has fallen 63.08% since its last report. The company recently rep...
Stifel analyst Mathew Blackman downgrades Apollo Endosurgery (NASDAQ:APEN) from Buy to Hold and announces $10 price target.
A new report was out about the performance of members of the U.S. Congress who bought and sold stocks and options in 2022. The...
Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointe...